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groups are described here for children (proxy EQ-5D and KS) and parents (EQ-5D).
Optimal compliance: proxy EQ-5D 0.8257, KS 47.5152, EQ-5D 0.8331. Suboptimal
compliance: proxy EQ-5D 0.7321, KS 42.7671, EQ-5D 0.8050. Medication use stopped:
proxy EQ-5D 0.7635, KS 42.5969, EQ-5D 0.8169. Remission after medication use:
proxy EQ-5D 0.8518, KS 45.8929, EQ-5D 0.8220. Naïve to medication: proxy EQ-5D
0.7719, KS 43.3744, EQ-5D 0.7899. CONCLUSIONS: Children with a good compliance
to medication and naïve children have a better QoL compared to non-compliant
children and children who stopped treatment (non-remission). The QoL of children
in remission is better than the QoL of children using medication. QoL of parents
follows a similar pattern.
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OBJECTIVES: To test the characteristics of a QUICK Questionnaire-Short version
(Q10) as diagnostic instrument for wearing-off phenomenon (WO) in Parkinson’s
disease (PD) patients. METHODS: Observational, cross-sectional, multicenter, and
national study developed in clinical practice. The study was developed in two
consecutive phases: I, to determine the sensitivity and specificity of Q10; and II: to
assess the usefulness (investigators) and the ability and ease of use (patients) of
Q10 questionnaire. Furthermore, the prevalence of WO among PD patients consec-
utively attending the specialist was also assessed (phase II). Patients 30 years old
at the onset of the disease with5 years from diagnosis and under treatment were
selected.RESULTS: In phase I, 162 patients were included, 67.49.7 years old, 53.8%
males, and 3.11.4 years from diagnosis. Most of them (85%) were in Hoehn-Yahr
stage 2-3. WO was presented in 64.8% (33.3% mild; 31.5% moderate/severe). Q10
was completed in 6.64.9 minutes. With two positive responses the Q10 showed
good sensitivity (90%) and moderate specificity (70%) and with 3 positive responses
both values reached an arbitrarily hypothesized 75% threshold (sensitivity: 81%;
specificity: 75%). The mean usefulness Q10 score was good [7.3 (1.6), scale 1-10]. In
phase II, most patients considered Q10: easy to understand (80.6%), reflect their
present situations (78.8%), and useful to communicate discomfort to the doctor
(80.6%). The prevalence of WO among the total PD patients attending to the neu-
rologist was of 59.0%, higher in males (64.9%), Hoehn-Yahr staging (80%, 3-4 stage)
and in patients with more time of PD evolution (71.9%). CONCLUSIONS: The Q10 is
a useful instrument for screening and diagnosis of WO, showing good sensitivity
and specificity, as well as, good usefulness, ability and ease to use. Almost two out
of three PD patients attending to the neurologist presented WO.
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OBJECTIVES: Develop a cross-cultural adaptation, English to Spanish, of the Clin-
ically Useful Depression Outcome Scale (CUDOS): a validated instrument to assess
depressive symptoms in patients with major depressive disorder (MDD).
METHODS: CUDOS is a brief self-administered scale with 18 items assessing all of
the DSM-IV inclusion criteria for MDD, psychosocial impairment and patients’
quality of life. Three independent translators (2 Spanish and 1 English) performed
forward-backward translations of the original scale. Draft version was reviewed by
an expert panel (4 general practitioners, 1 psychiatrist, and 2 psychologists) and
tested in 19 adult patients with MDD. Regarding experts’ and patients’ responses,
comprehension and importance (C/I) of each item were evaluated using a Likert
scale ranging from 0 (lowest level of C/I) to 4 (highest level of C/I). Furthermore,
feasibility, ceiling and floor effects and reliability were preliminary analyzed.
RESULTS: According to experts’ criteria, mean C/I values of items were over 2
points (comprehension mean range: 3.25-4 & importance mean range: 2.5-4). Re-
garding patients’ responses, acceptable mean values in comprehension (range:
2.26-3.37) were obtained. However, 4 items were modified to improve comprehen-
sion: loss of interest in usual activities, psychomotor retardation, indecisiveness
and hopelessness Patients reported low importance scores in items related to
thoughts of death (mean 1.42), suicidal ideation (mean 1.26), guilt (mean 1.79),
hypersomnia (mean 1.37) and insomnia (mean 1.78). Missing data was only
found in 2 patients. Internal consistency was high (Cronbach  .886), Neither item
ceiling nor floor effects were observed and patients perceiving a moderate to severe
psychosocial impairment obtained higher CUDOS scores –indicating a higher im-
pact- than those with mild or null impairment (Mann-Whitney U9.500; p.019).
Finally, the Spanish version of the CUDOS was reached by consensus.
CONCLUSIONS: The original CUDOS instrument was culturally adapted into Span-
ish. Psychometric analyses are needed to validate this measure in Spain.
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OBJECTIVES: FDA guidance on the use of Patient Reported Outcomes (PRO) for
product labeling claims emphasizes the importance of documented evidence of
patient input in PRO instrument development. A review of existing PROs used in
Major Depressive Disorder (MDD) suggested the need to conduct qualitative re-
search with patients with MDD to better understand their experience of MDD and
develop an evaluative instrument with content validity. The aim of this study was
to develop such a measure. METHODS: Ten MDD severity-specific focus groups
(n3-4 patients per group; total n38) with adult patients between the ages of 18
and 65 having a clinician-confirmed diagnosis of MDD and varying in severity
levels as defined by the DSM-IV TR criteria were conducted in January 2009.
Grounded theory data collection and analysis methods were used including an
open-ended discussion guide, an iteratively developed coding scheme, and the
comparison of coded segments of patients’ quotes to identify the patient experi-
enced signs and symptoms of MDD. Saturation of concepts, where no new relevant
information emerges in later interviews, was assessed. A new PRO instrument for
MDD was developed; cognitive interviews (n20) were conducted to test its content
validity in terms of item relevance and comprehension, comprehensiveness, in-
structions, recall period and response categories.RESULTS:Thirty-five unique con-
cepts falling into the following 6 domains: emotional symptoms; ideation symp-
toms; neuro-vegetative or somatic symptoms; physical impact; social impact; and
cognitive impact were elicited. Concept saturation was achieved for each of the
symptom concepts across severity levels. The MDD PRO instrument includes 15
daily and 21 weekly items. Cognitive interviews supported its content validity.
Items were revised, deleted, or moved from daily to weekly assessment based on
cognitive interview results CONCLUSIONS: Rigorous qualitative research resulted
in the development of a PRO measure for MDD with supported content validity; its
psychometric properties and responsiveness requires assessment.
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OBJECTIVES: Substitution therapy is commonly used across the world for the treat-
ment of opioid dependence (OD), yet little evidence exists examining country-
specific differences between acceptance and effectiveness of this treatment. The
purpose of this study was to examine differences between patient demographics,
treatment accessibility, and attitudes toward substitution therapy among OD pa-
tients in Germany and Italy.METHODS:A telephonic survey, initiated by the Italian
Federation of Operators of Dependences Departments and Services, examining
substitution therapy was administered to OD patients across two countries: Ger-
many (n200) and Italy (n378). The survey assessed experiences prior to and
during substitution therapy. RESULTS: Italian patients reported being in better
physical and mental health than German patients (p’s 0.001); were more likely to
get information about substitution therapy from family members than German
patients (8.9% vs. 3.2%, 2  5.22; p  0.05); and were more likely to report that it
was either very easy or fairly easy to find a doctor from whom they could receive
substitution treatment than German patients (89.9% vs. 68.7%, 2  40.35; p 
0.001). In contrast, German patients were more likely to get information from other
drug users (63.9% vs. 47.7%, 2 10.72; p 0.01) or their family physicians (14.6% vs.
4.3%, 2  14.59; p  0.0001), and were also more likely than Italian patients to
misuse their substitution drug by either snorting (11.5% vs. 3.2%, 2  15.94; p 
0.0001) or injecting it (18.5% vs. 11.1%, 2  6.05; p  0.05). CONCLUSIONS: The
present results highlight key differences in patient attitudes and experiences re-
garding substitution therapy. Differences in social and institutional attitudes, in
addition to cultural norms and health care policies, may explain the present find-
ings, which demonstrate the complexity of the OD population.
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OBJECTIVES: This research uses Cox regression to analyze relapse patterns of
adults treated for substance use disorder (SUD). The objective is to evaluate the role
psychosocial, treatment and environmental characteristics play in the relapse pro-
cess. While relapse is a much-studied phenomenon, there is no research describing
in detail how the risk of relapse changes over time (especially in the months im-
mediately following primary treatment) given known protective factors. Since SUD
is a chronic relapsing disorder, it is important to understand ways treatment gains
can be maintained. METHODS: Subjects are 408 adults discharged between 2000-
2009 from an ASAM-defined Level 1.A primary inpatient treatment program. Data
were collected via a 215-item questionnaire as part of the treatment program’s
annual outcomes evaluation. The sampling frame was people who successfully
completed treatment and who gave consent. The response rate was 56 percent. The
researchers obtained the treatment records of each person completing the ques-
tionnaire and matched the treatment outcomes from the questionnaire to treat-
ment and sociodemographic variables present in the treatment records. A compre-
hensive data set was created from these two sources. Data were analyzed using
Cox proportional hazard regression. RESULTS: Statistically significant covariates
include: home environment variables (those with supportive people at home are
3.17 times less likely to relapse; those with supportive spouses are 4.91 times less
likely to relapse) and support group variables (those attending self-help meetings
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